Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource  rightarrow Monoclonal Antibody Blog  rightarrow anti-CD229 antibody  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Blogs moreseparator
separator
 • anti-CTGF antibody blog
 • anti-Rab5a antibody blog
 • anti-HMGB1 antibody blog
 • anti-MAdCAM-1 antibody blog
 • anti-IgG4 antibody blog
 • MFGE8 antibody blog
 • DSG3 antibody blog
 • anti-CD4 antibody blog
 • anti-Nidogen/Enactin antibody blog
 • anti-USP7 antibody blog
 • FSCN1 antibody blog
 • anti-TFPI antibody blog
 • anti-UBB antibody blog
 • anti-160 kDa Neurofilament antibody blog
 • anti-CSFV Structural Glycoprotein antibody blog
 • anti-APAF1 antibody blog
 • anti-Trpc4 antibody blog
 • anti-CD4 antibody blog
 • anti-CD30/TNFRSF8 antibody blog
 • anti-N/A antibody blog
separator
Blog Categories separator
separator
 • Assay Kit Blogs
 • Biochemical Blogs
 • cDNA Clone Blogs
 • Monoclonal Antibody Blogs
 • Polyclonal Antibody Blogs
 • Rec/Purified Protein Blogs
 • Popular Product Blogs
separator
Our Best Sellers moreseparator
separator
 • Uteroglobin Related Protein 1 (SCGB3A2) Antibody
 • Lipocalin 1 (LCN1) ELISA Kit
 • VEGFB Antibody
 • SRPX Antibody
 • CDK9 (CDK-9) ELISA Kit
 • BATF3 Antibody
 • LYN Antibody
 • Antifungal protein (afp) Recombinant Protein
 • Gram Negative Endotoxin (E. coli 0:111 B4 J5) Antibody
 • ERK2 ELISA Kit
 • DYRK4 Antibody
 • GATA3 ELISA Kit
 • Collagen Type I Alpha 1 (COL1a1) Recombinant Protein
 • Ack1 (TNK2) Antibody
 downarrow more ...
separator

anti-CD229 antibody product blog

separator
Posted on 2015-12-12 20:21:48 by mybiosource_staff
Share it on ...     
separator
separator
Tags: Antibody; Monoclonal Antibody; CD229; anti-CD229 antibody;
separator
The CD229 ly9 (Catalog #MBS213728) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s CD229 can be used in a range of immunoassay formats including, but not limited to, Flow cytometry (FC/FACS).
Flow Cytometry: Use 10ul of the suggested working dilution to label 106 cells in 100ul or 100ul whole blood.
Flow Cytometry: Maximum Dilution: Neat. Researchers should empirically determine the suitability of the CD229 ly9 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.

The CD229 ly9 product has the following accession number(s) (GI #75991709) (NCBI Accession #NP_001028839.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.

To buy or view more detailed product information and pricing, please click on the technical datasheet page below:


Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the MOUSE ANTI HUMAN CD229:RPE with the following immunoassay(s):
Testing Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free (MBS210211))
Testing Data CD229.

Testing Data (Published customer image: Correlation between SLAMF3 expression and HCC cell proliferation.(A) Effects of the introduction of specific siRNAs on SLAMF3 expression in Huh-7 cells. Cells were transiently transfected with a scrambled siRNA (Sc) or one of two pre-designed anti-SLAMF3 siRNAs (referred to as #2 and # 3); SLAMF3 expression was measured by Western blot analysis (anti-SLAMF3, K12). One representative of two independent experiments is shown. (B) siRNA-treated Huh-7 cells were cultured and proliferation was assayed in a Trypan blue exclusion test after 48 h. Proliferation is presented as the mean number of viable cells +/- SD (n = 5; statistical significance: ***p)
Testing Data CD229.

Testing Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD229 : RPE)
Testing Data CD229.

Testing Data (Published customer image SLAMF3 over-expression increases hepatocyte permissiveness to HCV. Huh-7 cells were transfected with empty vector pBud (mock) or human SLAMF3 (to yield Huh-7+ cells) and incubated with HCVcc. (A) SLAMF3 expression was analyzed by flow cytometry (HLy9.1.25 clone) and (B) visualized by confocal microscopy in one out of three experiment. Unshaded histograms show the isotype-matched control (Co) and shaded histograms show SLAMF3 expression). (C, D, E) Infection was assessed at 4 and 72 h p.i. as the number of FFUs and (F and G) by flow cytometry analysis; (C) intracellular E2 (stained red) were measured at 4 h and 72 h p.i. Green staining corresponds to the SLAMF3 expression. One of three representatives independent experiments is shown. (D) The HCV permissiveness of Huh-7 mock and Huh-7+ cells was evaluated in terms of the number of FFUs based on intracellular E2 viral protein staining and (E) fluorescent microscopy analysis (mean of five experiments; error bars: SD; *p)
Testing Data CD229.

Testing Data (Published customer image: SLAMF3 expression is repressed in tumour cells from ten resected HCC patients. (A) SLAMF3 mRNA expression was analysed in hepatocytes from resected HCC patients. Specific amplification of SLAMF3 mRNAs using PCR (representative patients #2, #7 and #12) and quantitative PCR in tumour tissues (T) and peritumoral tissues (pT) presented separately (B) and as median (**p)
Testing Data CD229.

Testing Data (Published customer image: Restoration of SLAMF3 expression in HCC cells inhibits MAPK ERK1/2, JNK and mTOR pathways and induces caspase-dependent apoptosis.(A) SLAMF3 expression was confirmed by Western blot analysis in SLAMF3-over-expressing Huh-7 and mock cells at 48 h post-transfection. ERK1/2, JNK, p38, AKT and mTOR proteins were detected as controls. The activation levels of MAPK ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/Tyr 185), p38 (Thr 180/Tyr 183), PI3K (p85/p110 Thr 467/Tyr 199), AKT (Ser 473, Thr 308) and mTOR (Ser 2448, Ser 2481) are represented. One of three representative experiments is shown here. (B) The results of an active caspase assay based on cell-permeable fluorochrome inhibitor of caspases (FLICA). Caspase activity was evaluated in HCC cells (Huh-7 and HepG2 lines) at the indicated times after the ectopic introduction of SLAMF3 vector. Caspase activity is shown in the SLAMF3neg subpopulation (in white) and the SLAMF3pos (overlaid in grey) subpopulation from one representative of two independent experiments.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data CD229.

Testing Data (Published customer image: Expression of SLAMF3 assessed by flow cytometry analysis after transfection with vector coding for SLAMF3 or an empty vector (Mock) in Huh-7 and HepG2 cells. SLAMF3 staining (in grey) is overlaid by negative control (in white). One of four independent experiments is shown. doi:10.1371/journal.pone.0082918.s002From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data CD229.

Testing Data (Published customer image: Expression of SLAM-R family by HHPHs and Huh-7 and HepG2 human HCC cell lines. SLAM-Rs were stained with specific antibodies against SLAMF1 (CD150), SLAMF2 (CD84), SLAMF4 (CD224) and SLAMF6 (NTBA) (grey) or with matched isotype controls (empty). One of four independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data CD229.

Testing Data (Published customer image: Effect of SLAMF3 expression on the organization of the actin cytoskeleton. Cells (Huh-7) were stained with phalloidin (rhodamine, red) and anti-SLAMF3 (FITC, green) and SLAMF3 positive (Huh-7-SLAMF3pos) and SLAMF3-negative (Huh-7-SLAMF3pos) cells were examined under the microscope. One representative of two independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data CD229.

Testing Data (Published customer imageSLAMF3 blockade in human hepatocytes is associated with lower susceptibility to HCV. (A) SLAMF3 was stained in primary human hepatocytes (PHHs) and cells from the Huh-7 human hepatoma cell line with a specific antibody (HLy9.1.25 clone; grey) and an isotype-matched control (empty). One of four independent experiments is shown. Huh-7 cells were transfected with scrambled control (sc) siRNA or three specific siRNAs (#1, #2 and #3) targeting SLAMF3, prior to infection with HCVcc; siRNA efficiency was checked by quantifying SLAMF3 mRNA (B) and the CD81 expression level (C) by flow cytometry analysis at 48 h post-transfection. Results are presented as the mean +/-SD (n = 3). Intracellular viral RNA was quantified at 72 h p.i. (D) and the infection was measured at 72 h p.i. by focus-forming units FFUs counting (E) (as inhibition percent; mean of three independent experiments; error bars: SD. **p)
Testing Data CD229.

horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions